Avadel Pharmaceuticals (AVDL) is facing a proxy battle from ASL Strategic Value Fund, which urged shareholders Monday to vote against all company director nominees at the annual meeting scheduled for July 29.
In an open letter, ASL accused Avadel's management of destroying significant shareholder value, citing alleged "missteps with the launch of Lumryz" resulting in missed revenue of $600 million to $800 million and earnings of around $5 to $7 per share.
ASL also called for the issuance of contingent value rights linked to potential recoveries from six ongoing legal cases against Jazz Pharmaceuticals, including one case that could result in over $1 billion in damages.
The fund also reiterated its call for Avadel to hire an investment bank to help "monetize the significant value inherent" in Lumryz.
Avadel did not immediately respond to requests for comment from MT Newswires.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.